CompletedPhase 2NCT00005836
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Paula M. Fracasso, MD, PhD, MD, PhDWashington University Siteman Cancer Center
- Intervention
- oxaliplatin(drug)
- Eligibility
- FEMALE
- Timeline
- 2000 – 2004
Study locations (30)
- University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
- CCOP - Greater Phoenix, Phoenix, Arizona, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Chao Family Comprehensive Cancer Center, Orange, California, United States
- Women's Cancer Center, Palo Alto, California, United States
- University of Colorado Cancer Center, Denver, Colorado, United States
- Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington D.C., District of Columbia, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Emory University Hospital - Atlanta, Atlanta, Georgia, United States
- MBCCOP - Hawaii, Honolulu, Hawaii, United States
- MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005836 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →